Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib as First-line Treatment in EGFR-mutated NSCLC
NCT06674343Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06674343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674343.